Gilead Sciences CFO Dickinson sells $295k in shares

Chief Financial Officer Andrew D. Dickinson of Gilead Sciences (NASDAQ:GILD) sold 2,500 shares of common stock on October 15, 2025, at a price of $118.08, for a total transaction value of $295,200. The transaction comes as the biotech giant, currently valued at $146 billion, trades near its 52-week high of $121.83, having delivered an impressive 30% return year-to-date. According to InvestingPro analysis, the stock is currently trading close to its Fair Value.

Following the transaction, Dickinson directly owns 157,055 shares of Gilead Sciences. The sale was executed under a Rule 10b5-1 trading plan adopted on August 29, 2024. InvestingPro data reveals that Gilead maintains a strong financial health score of "GREAT" and offers a 2.68% dividend yield. For deeper insights into insider trading patterns and 10+ additional ProTips, consider exploring Gilead’s comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, Gilead Sciences has announced significant developments concerning its cancer drug Trodelvy. The company is set to present late-breaking data at the European Society for Medical Oncology 2025 Congress, showcasing results from the Phase 3 ASCENT-03 study. This study evaluated Trodelvy as a first-line treatment for metastatic triple-negative breast cancer and met its primary endpoint, showing a notable improvement in progression-free survival compared to chemotherapy. Additionally, RBC Capital has raised its price target for Gilead Sciences to $100, citing the promising early launch of Gilead’s new drug, Yeztugo, which may exceed initial sales expectations. Furthermore, Bernstein has reiterated an Outperform rating for Gilead, following the company’s settlement of patent litigation with three generic manufacturers, extending the market exclusivity for its HIV treatment Biktarvy until April 2036. Needham also maintained a Buy rating for Gilead, highlighting the potential of its early-stage inflammation pipeline for long-term growth. These developments underscore Gilead’s strategic efforts in advancing its drug portfolio and securing market positions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.